NMG
EDIT icon

New Millennium Group’s Editas Medicine EDIT Stock Holding History

New Millennium Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$220 – 519
2025
Q2 		$220 Buy
+100
New +$164 ﹤0.01% 392
2023
Q2 		– Sell
-11
Closed -$80 – 423
2023
Q1 		$80 Hold
11
– – ﹤0.01% 425
2022
Q4 		$98 Hold
11
– – ﹤0.01% 458
2022
Q3 		$0 Hold
11
– – ﹤0.01% 375
2022
Q2 		$0 Buy
+11
New +$147 ﹤0.01% 365

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

New Millennium Group's EDIT Position: Q3 2025 in Review

New Millennium Group sold out of Editas Medicine (EDIT) in Q3 2025, closing a stake of 100 shares — an estimated $220 sold.

New Millennium Group first reported a position in EDIT in Q2 2022 and held it in 5 quarters. The position peaked at $220 in Q2 2025. 193 funds tracked by Wall St. Rank hold EDIT as of Q3 2025.

  • New Millennium Group reported no remaining Editas Medicine position as of Q3 2025 after selling out during the quarter.
  • New Millennium Group sold 100 Editas Medicine shares in Q3 2025, an estimated $220.
  • New Millennium Group first reported a position in Editas Medicine in Q2 2022 and held it in 5 quarters.
  • New Millennium Group's Editas Medicine position peaked at $220 in Q2 2025.
  • 193 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2025.

Based on New Millennium Group's 13F filing for Q3 2025, filed 10 Nov 2025.